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Immunochemical faecal occult blood tests have shown a greater sensitivity than guaiac test in colorectal cancer screening, but optimal
number of samples and cutoff have still to be defined. The aim of this multicentric study was to evaluate the performance of
immunochemical-based screening strategies according to different positivity thresholds (80, 100, 120ngml
 1) and single vs double
sampling (one, at least one, or both positive samples) using 1-day sample with cutoff at 100ngml
 1 as the reference strategy. A total
of 20596 subjects aged 50–69 years were enrolled from Italian population-based screening programmes. Positivity rate was 4.5% for
reference strategy and 8.0 and 2.0% for the most sensitive and the most specific strategy, respectively. Cancer detection rate of
reference strategy was 2.8%, and ranged between 2.1 and 3.4% in other strategies; reference strategy detected 15.6% advanced
adenomas (range¼10.0–22.5%). The number needed to scope to find a cancer or an advanced adenoma was lower than
2 (1.5–1.7) for the most specific strategies, whereas it was 2.4–2.7, according to different thresholds, for the most sensitive ones.
Different strategies seem to have a greater impact on adenomas rather than on cancer detection rate. The study provides
information when deciding screening protocols and to adapt them to local resources.
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Faecal occult blood testing (FOBT)-based screening has been
proven effective in reducing mortality from CRC (Hewitson et al,
2007). Recently, immunochemical tests (IFOBT) have been shown
to be more sensitive than classic guaiac testing, and, as IFOBTs are
specific for human haemoglobin (Hb), they do not require dietary
restrictions, thus potentially improving screening acceptability.
Moreover, some studies (Castiglione et al, 2000; van Rossum et al,
2008) suggested that 1-day IFOBT is more accurate (in terms of
sensitivity/specificity ratio) compared to 3-day guaiac testing.
Single sampling would enhance screening feasibility, and likely
compliance, which has always been a critical factor (Vernon, 1997;
van Rossum et al, 2008). Based on these considerations, latex
agglutination test (LAT) has been adopted as 1-day testing in the
Florence screening programme (Castiglione et al, 2000), using a
positivity threshold of 100ngml
 1 Hb of sample solution; the same
strategy has been then adopted by all Italian FOBT-based screening
programmes (Zorzi et al, 2008).
Quantitative IFOBT assays (such as LAT), which allow the
adjustment of positivity thresholds to fit screening aims are now
available. Earlier studies (Itoh et al, 1996; Nakama et al, 1999, 2000;
Castiglione et al, 2002; Edwards, 2005; Chen et al, 2007; Levi et al,
2007) have evaluated the impact of using different IFOBT positivity
thresholds and single vs multiple sampling in terms of sensitivity/
specificity ratio. The aim of this study is to provide further
information on the diagnostic accuracy and colonoscopy workload
of LAT-based screening using different positivity thresholds (X80,
X100 and X120ngml
 1), and single vs multiple samplings
(1 vs 2 days).
MATERIALS AND METHODS
This multicentric study involved four CRC population-based
screening programmes of Northern (Alto Vicentino, Bussolengo
and Feltre Local Health Units) and Central Italy (Florence ISPO
Cancer Prevention and Research Institute), currently inviting
residents aged 50–69 years to biennial IFOBT screening. The main
characteristics of Italian screening programmes have already been
described elsewhere (Zorzi et al, 2008). For this study, a special
screening protocol was implemented. The study was submitted and
approved by the Committees for Ethics of involved screening
programmes. Participation to the study was offered to all subjects
of target population who lived in those areas selected for the study.
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sSubjects received a dedicated invitation letter, which invited them
to screening and explained the aims of the study. An informed
consent was required to all attending subjects who accepted to
participate in the study. Attendees received two test tubes for
collecting faeces from two consecutive bowel movements. People
who refused to participate in the study could benefit from routine
screening (one sample with positivity threshold at 100ngml
 1).
Tubes were marked to identify the first and the second samplings.
Samples were collected and stored at 41C until test development,
usually within a week after collection.
Latex agglutination test assay (OC-Hemodia, Eiken, Tokyo,
Japan, distributed by Alfa Wassermann, Milano, Italy) was
employed. Quantitative assessment of human Hb was obtained
through an antigen–antibody agglutination reaction using human
anti-Hb polyclonal antibodies adsorbed on polystyrene particles:
agglutination was measured as a 660-nm absorbency increase,
proportional to Hb content in tested samples. The OC-Hemodia
assay was developed by means of the OC-Sensor Micro instru-
ments (Eiken, Tokyo, Japan), supplied by the distributor. Every
screening programme had a reference laboratory where tests were
processed by an own dedicated instrument. All the laboratories
involved in the study cooperated in a national network for
interlaboratory quality control, with the aim of monitoring the
reproducibility of the FOBT technique.
Participants were instructed to return the test as soon as
possible to avoid degradation of Hb in the samples. If the test
could not be returned immediately, storage in a domestic
refrigerator was advised.
Subjects with 479ngml
 1 Hb, in at least one sample, were
recalled for colonoscopy assessment, whereas subjects with
o80ngml
 1 Hb received a negative report by mail, recommend-
ing biennial rescreening. Incomplete colonoscopy prompted
double contrast X-ray barium enema. Inadequate samples
occurred in the absence of faecal material. No cutoff based on
storage duration was used to define test as non-analysable.
Subjects returning only one adequate sampling were excluded
from the study. Subjects returning two inadequate samplings were
advised to repeat the sampling.
The following screening strategies were compared: one sample
with three different positivity thresholds (X80, X100 and
X120ngml
 1), and two samples with the same three thresholds,
with at least one or both samples positive. One-day testing was
determined as the result of the second sampling to simulate the
actual exposure to degradation of Hb in a 1-day strategy.
Advanced adenoma was defined as any adenoma larger than
9mm, and/or with a villous histological component higher than
20%, and/or with severe dysplasia. When more than one lesion was
present, the subject was classified according to the most severe
lesion. For this study, ‘significant neoplasia’ was defined, and is
henceforth referred to as the sum of cancers and advanced
adenomas. Performance was assessed according to positivity rate
(PR¼proportion of positive FOBT among subjects returning the
samples), detection rate (DR¼cancers or significant neoplasia
detected among 1000 screened subjects) and positive predictive
value (PPV¼cancers or significant neoplasia detected among 100
FOBTþcolonoscopy assessments). The number needed to scope
(NTS) was calculated as the number of FOBTþcolonoscopies
needed to find one person with cancer or with significant
neoplasia. Screening strategies were compared with the one
presently adopted by Italian screening programmes (1-day testing
at X100ngml
 1), henceforth referred to as ‘reference strategy’.
Statistical analysis
Differences between tests were checked by w
2 method, significance
being set at Po0.05. Differences between means were checked by
the Student’s t-test and analysis of variance (ANOVA). Con-
fidences intervals at 95% (95% CI) of PR, DR and PPV were
calculated using binomial distribution. To take into account
multitesting, statistical comparisons among different strategies
were carried out assuming the Bonferroni correction (Greenland
and Rothman, 1998). Statistical analysis was performed using
STATA 8.2 SE software.
RESULTS
From September 2005 to June 2007, 20596 subjects aged 50–69
years in their first screening round were enrolled in the study.
Twenty-two subjects returned only one FOBT sample were
excluded from the study. Seventeen subjects returned two
inadequate samplings were advised to repeat sampling. Out of
them, 12 returned a double adequate sampling and they were
included in the study. Two subjects returned again two inadequate
samplings, whereas three subjects did not repeat any sampling.
These latter five subjects were excluded from the study.
The principal characteristics of the study cohort are shown in
Table 1. Mean attendance rate to the study was 56.2%, ranging
from 49.1 to 77.9%. Mean acceptance rate to participate in the
study for screening attendees was 96.1%.
Overall, the mean age was 59.9 years (s.d.¼5.6), with no
difference between programmes, apart from Florence (mean 61.0
years, s.d.¼5.3), where a higher proportion of subjects aged 60–
69 years were enrolled. Overall, a slight prevalence of women (53.8
vs 46.2%) was observed, even more so in the Florence programme
(women¼56.5%). Positivity rate varied among centres
(range¼6.7–9.2%) at a significant level (Po0.05). Average
compliance to colonoscopy was 89.0%, ranging from 96.2% in
Alto Vicentino to 83.5% in Florence. Average completed colono-
scopy rate was 95.2%.
Positivity rate according to the different screening strategies is
reported in Table 2. As expected, 1-day strategies with the lower
(X80ngml
 1) or higher (X120ngml
 1) threshold were asso-
ciated with a slight increase (þ0.9%) or decrease ( 0.5%) of PR,
compared to the reference strategy, respectively. Positivity rates of
2-day strategies with at least one positive test were notably higher
than the reference strategy, differences ranging from þ1.4%
(threshold X120ngml
 1)t oþ3.5% (threshold X80ngml
 1).
Two-day strategies with both positive test results significantly
decreased PR. All differences among each strategy and the
reference strategy were statistically significant at Po0.00625
(threshold for significance after Bonferroni correction), except
strategy of 1-day and cutoff X120ngml
 1 (P¼0.01).
Overall, 69 cancers and 465 advanced adenomas were diagnosed.
Cancer stage was I in 41 (59.4%), II in 13 (18.8%), III–IV in 15
(21.7%). No statistically significant difference in stage distribution
was found among different strategies (P-values from 0.80 to 0.99),
but the study was not designed and specifically not powered to find
existing differences.
Detection rate for cancer and significant neoplasia are shown in
Table 3. The reference strategy detected 2.8% cancers. Compared
to the reference strategy, 2-day strategies with at least one positive
result had a slightly higher DR for cancer (from þ0.5 to þ0.6%,
according to the positivity cutoff), whereas the more specific
strategies (2-day with both positive results) had a slightly lower DR
(from  0.5 to  0.6%). No observed difference in DR reached
statistical significance (P¼ 0.20–0.85).
The reference strategy detected 18.4% significant neoplasia, and
more substantial differences in significant neoplasia DR were
observed with respect to other strategies than for cancer DR. The
most sensitive strategy (2-day with at least one positive sample at
X80ngml
 1) allowed for an incremental DR of 7.5%, whereas the
most specific strategy (2-day with both positive samples at
X120ngml
 1) decreased the DR by 6.3%. After Bonferroni
correction, all the observed differences in significant neoplasia
DR among the reference strategy and strategies based either on
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statistically significant with the only exception of 1-day strategy
at X120ngml
 1 (P¼0.02).
Table 4A shows PPV for cancer and significant neoplasia with
different strategies. The PPV of the reference strategy for cancer
was 6.9%. All differences among each strategy and the reference
strategy for cancer were not statistically significant at Po0.00625
(threshold for significance after Bonferroni correction) with
P-values 0.00630–0.59.
The PPV of the reference strategy for significant neoplasia was
45.8%. After Bonferroni correction, all the observed differences in
significant neoplasia PPV among the reference strategy and
strategies based either on both positive samples or at least one
positive sample were statistically significant with the only
exception of 1-day strategy at X120ngml
 1 (P¼0.0485).
As expected, lowering the threshold or adopting a 2-day strategy
with at least one positive result reduced PPV; in particular, the
introduction of a second sample was associated with a significant
decrease of PPV for significant neoplasia ( 9.4% in the 2-day
strategy at X80ngml
 1). The most specific strategies, on the
contrary, determined a statistically significant increase of PPV for
significant neoplasia ranging from 12.6 to 20%, as the positivity
threshold increased.
Table 4B shows NTS for cancer and significant neoplasia with
different strategies. The NTS of the reference strategy for cancer
and significant neoplasia was 14.5 and 2.2, respectively. The
number needed to scope to find a significant neoplasia was lower
than 2 for the 2-day strategies with both positive samples (1.7, 1.6
and 1.5 according to the threshold at 80, 100 or 120ngml
 1,
respectively). On the contrary, for the most sensitive 2-day
strategies, the number of colonoscopy examinations needed to
detect a significant neoplasia ranged from 2.4 to 2.7, by lowering
the threshold from 120 to 80ngml
 1. For the 1-day strategies, this
indicator was about 2 (range¼2.1–2.3).
Table 5 summarises the main results of the study according to
the different strategies. The 2-day strategy with at least one
positive result at X100ngml
 1 identified 21% more cancers and
26% more advanced adenomas than the reference strategy,
Table 2 Positivity rate (%) by screening strategy and difference with the reference strategy
a
Positivity rate  100 screened subjects
2–day strategy
Cutoff 1-day strategy (at least one sample with positive result) (both samples with positive results)
X80ngml
 1 5.5 8.0 2.8
+0.9 (0.5–1.4) +3.5 (3.0–3.9)  1.7 ( 2.1 to  1.4)
X100ngml
 1 4.5
a 6.7 2.3
(reference) +2.2 (1.7–2.6)  2.2 ( 2.6 to  1.9)
X120ngml
 1 4.0
b 5.9 2.0
 0.5 ( 0.9 to  0.1) +1.4 (1.0–1.8)  2.5 ( 2.8 to  2.2)
Statistical comparison of strategies (with Bonferroni correction for multitesting). 95% CI (confidence interval) of difference is given in brackets. All differences among each strategy
and the reference strategy were statistically significant at Po0.00625 (threshold for significance after Bonferroni correction), except strategy of 1-day and cutoff X120ngml
 1.
aReference strategy: 1-day and cutoff X100ngml
 1.
bP¼0.0113.
Table 1 Main characteristics of subjects enrolled in the study by screening programme
Programme Florence Bussolengo Alto Vicentino Feltre Overall
Study population
Number of invited subjects 14969 13201 5768 2708 36646
Participants to routine screening who refused to
participate in the study (%)
3.6 4.5 4.1 4.0 3.9
Number of recruited subjects 7343 7211 3932 2110 20596
Compliance to the study (%) 49.1 54.6 68.2 77.9 56.2
Age class (%)
50–59 years 44.1 56.3 54.5 56.1 51.6
60–69 years 55.9 43.7 45.5 43.9 48.4
Sex (%)
Male 43.5 47.4 48.1 48.0 46.2
Female 56.5 52.6 51.9 52.0 53.8
Subjects with a positive test (n)
a 546 664 265 171 1646
Positivity rate (%)
b 7.4 9.2 6.7 8.1 8.0
Compliance to colonoscopy (%)
c 83.5 90.1 96.2 91.2 89.0
Colonoscopies performed (n) 456 598 255 156 1465
Complete colonoscopy rate (%)
d 96.1 93.3 96.1 98.7 95.2
Diagnosed lesions (n)
Cancers 24 26 12 7 69
Advanced adenomas 136 192 91 46 465
aAt least one sample result at X80ngml
 1.
bMultiplied with 100 screened subjects.
cMultiplied with 100 positive subjects.
dMultiplied with 100 colonoscopies.
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sTable 3 Detection rate (%) for cancer and for significant neoplasia
a by screening strategy and difference with the reference strategy
b
Detection rate  1000 screened subjects
2–day strategy
Cutoff 1-day strategy (at least one sample with positive result) (both samples with positive results)
Cancer
X80ngml
 1 2.9 3.4 2.3
+0.1 ( 0.9 to 1.1) +0.6 ( 0.5 to 1.7)  0.5 ( 1.5 to 0.5)
X100ngml
 1 2.8
b 3.4 2.1
(reference) +0.6 ( 0.5 to 1.7)  0.6 ( 1.6 to 0.3)
X120ngml
 1 2.7 3.3 2.1
 0.1 ( 1.1 to 1.0) +0.5 ( 0.6 to 1.5)  0.6 ( 1.6 to 0.3)
Significant neoplasia
X80ngml
 1 20.7 25.9
c 14.6
c
+2.3 ( 0.4 to 5.0) +7.5 (4.7–10.4)  3.8 ( 6.3 to  1.3)
X100ngml
 1 18.4
b 23.1
c 12.8
c
(reference) +4.7 (1.9–7.4)  5.6 ( 8.0 to  3.2)
X120ngml
 1 17.3 21.7
d 12.1
c
 1.1 ( 3.6 to 1.5) +3.3 (0.6–6.0)  6.3 ( 8.6 to  3.9)
Statistical comparison of strategies (with Bonferroni correction for multitesting). 95% CI (confidence interval) of difference is given in brackets.
aSignificant neoplasia:
cancerþadvanced adenoma (any adenoma larger than 9mm, and/or with a villous histological component higher than 20%, and/or with severe dysplasia).
bReference strategy:
1-day and cutoff X100ngml
 1.
cDifferences among strategy and the reference strategy were statistically significant at Po0.00625 (threshold for significance after Bonferroni
correction).
dNon-significant at Po0.00625 (P¼0.0168).
Table 4 Positive predictive value (PPV) (%) of FOBT+ colonoscopy for cancer and for significant neoplasia
a and number needed to scope (NTS) to find a
cancer or a significant neoplasia by screening strategy and difference with the reference strategy
b
2–day strategy
Cutoff 1-day strategy (at least one sample with positive result) (both samples with positive results)
(A) PPV 100 colonoscopies
Cancer
X80ngml
 1 5.9 4.7** 9.1
 1.0 ( 3.3 to 1.3)  2.2 ( 4.2 to  0.1) +2.2 ( 0.8 to 5.3)
X100ngml
 1 6.9
b 5.7 10.4***
(reference)  1.2 ( 3.4 to 0.9) +3.5 (0.1 to 6.9)
X120ngml
 1 7.6 6.2 11.6****
+0.7 ( 1.9 to 3.3)  0.7 ( 3.0 to 1.6) +4.7 (1.0 to 8.3)
Significant neoplasia
X80ngml
 1 42.7 36.5 58.5
 3.2 ( 7.8 to 1.4)  9.4 ( 13.6 to  5.2)
c +12.6 (7.2–18.1)
c
X100ngml
 1 45.8 38.9 62.4
(reference)  6.9 ( 11.3 to  2.6)
c +16.6 (10.9–22.3)
c
X120ngml
 1 48.4 41.3***** 65.8
+2.6 ( 2.3 to 7.6)  4.5 ( 9.0 to 0.0) +20.0 (14.1–25.8)
c
(B) NTS
d
Cancer
X80ngml
 1 17.0 (13.6–22.6) 21.2 (17.3–27.6) 11.0 (8.6–15.1)
X100ngml
 1 14.5 (11.6–19.4)
b 17.7 (14.4–23.0) 9.6 (7.5–13.4)
(reference)
X120ngml
 1 13.2 (10.5–17.6) 16.2 (13.1–21.0) 8.6 (6.8–12.0)
Significant neoplasia
X80ngml
 1 2.3 (2.2–2.5) 2.7 (2.6–2.9) 1.7 (1.6–1.9)
X100ngml
 1 2.2 (2.0–2.4)
b 2.6 (2.4–2.8) 1.6 (1.5–1.7)
(reference)
X120ngml
 1 2.1 (1.9–2.2) 2.4 (2.3–2.6) 1.5 (1.4–1.6)
Statistical comparison of strategies (adopting Bonferroni correction for multitesting). 95% CI (confidence interval) of difference is given in brackets.
aSignificant neoplasia:
cancer+advanced adenoma (any adenoma larger than 9mm, and/or with a villous histological component higher than 20%, and/or with severe dysplasia).
bReference strategy:
1-day and cutoff X100ngml
 1.
cDifferences among strategy and the reference were statistically significant at Po0.00625 (threshold for significance after Bonferroni correction).
Non-significant at Po0.00625, *P¼0.0277, **P¼0.0312, ***P¼0.0063, ****P¼0.0485.
dNTS: number of FOBT+colonoscopies needed to find a cancer or a significant
neoplasia.
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swhereas the 2-day strategy with at least one positive result at
X80ngml
 1 allowed to diagnose a further amount of advanced
adenomas (þ18%). Increasing the threshold reduced the screen-
ing sensitivity, but at X120ngml
 1, it still allowed for a 17.5%
cancer and 18% advanced adenoma incremental DR compared to
the reference strategy. On the contrary, using a more specific 2-day
strategy (with both samples at X80, X100 or X120ngml
 1)
would miss 21, 30 and 34% significant neoplasia compared to the
reference strategy, respectively.
In other words, compared to the reference strategy, the most
sensitive strategy prompted 638 more colonoscopies and detected
12 more cancers and 143 more advanced adenomas. Therefore, the
number needed to scope to detect one additional cancer was 53.2,
whereas 4.5 colonoscopies were necessary to detect one additional
advanced adenoma (see also Table 5). On the contrary, the most
specific strategy prompted 447 less colonoscopies compared to the
reference strategy, but missed 13 cancers and 116 advanced
adenomas. Spared colonoscopies per each missed cancers were
34.4, those per each missed advanced adenomas were 3.9.
DISCUSSION
In recent years, a general agreement that IFOBT is superior to
guaiac testing for screening purpose (Kahi et al, 2008; van Rossum
et al, 2008) has grown. The IFOBT also allows for quantitative
assay, and the positivity threshold may be adjusted to fit the local
clinical and/or economic setting. This issue has been addressed in
earlier studies (Nakama et al, 2000; Vilkin et al, 2005; Chen et al,
2007; Levi et al, 2007; Guittet and Launoy, 2008). In this study, we
focused on the balance between cancer and advanced adenoma DR
and colonoscopy workload by comparing different strategies using
different number of samples and positivity thresholds, as assessed
in a population-based screening service setting. To the best of our
knowledge, this is the first study that simultaneously evaluated
both these parameters in a large screening population sample.
Some slight differences in the distribution by age and sex were
observed among centres in the study. A higher proportion of older
(60–69 years) women in Florence compared to other centres is not
due to difference in age distribution of the invited population,
though a greater attendance in older women might be explained by
the fact that in Florence programmes for cervical and breast cancer
were activated many years ago and justifies higher awareness of
older women usually less complying to screening invitations.
Differences occurred among the four centres as far as PR and
DR are concerned. Such differences derived from the above-
mentioned different composition for age and sex of examined
population and probably from a different underlying incidence.
Nevertheless, it does not affect the validity of the study. In fact, the
aim of this study was to compare the performance of different
FOBT strategies. If we consider the rate ratio (RR) between the
most sensitive for significant neoplasia (subject invited to
colonoscopy if at least one out of two sample was higher than
80ngml
 1) and the less sensitive strategy (subject invited to
colonoscopy if both samples resulted higher than 120ngml
 1), we
can observe that this ratio resulted quite stable among the four
centres and without statistically significant differences. In fact, the
RRs (on brackets the 95% CI) were 2.0 (1.5–2.5), 2.2 (1.7–2.7), 2.3
(1.7–3.3) and 2.3 (1.4–3.8) for Florence, Bussolengo, Alto Vice-
ntino and Feltre, respectively.
It means that the results we can obtain for the overall study are
substantially valid also within each centre.
From a public health point of view, the choice of the best
screening test is a critical issue, which must take into account the
existing healthcare organisation and local resources. So far,
different choices have been adopted in countries where a CRC
screening programme has been (or is going to be) implemented on
a national basis. In Japan, the adopted strategy was biennial 2-day
I-FOBT (Monoheam) at X150ngml
 1, based on the studies of
Nakama et al (2000, 2001) suggesting that this strategy allows for
the best cost/effectiveness ratio. In the UK pilot study (UK
Colorectal Cancer Screening Pilot Group, 2004), a specific strategy
was adopted with guaiac testing without rehydration. In Italy, a
biennial strategy based on 1-day LAT at X100ngml
 1 has been
adopted (Zorzi et al, 2008). This choice was based on several
studies (Castiglione et al, 2000, 2002) and on an estimate of
programme sensitivity for cancer, which confirmed a higher
accuracy of 1-day IFOBT compared to guaiac testing (Zappa et al,
2001). On the whole, in respect to policies adopted in other
European countries (UK Colorectal Cancer Screening Pilot Group,
2004), the Italian strategy (biennial one-time IFOBT at
X100ngml
 1) favoured a sensitive approach, at the cost of
reduced specificity.
Italian results have been confirmed by a recent study of van
Rossum et al. (2008), which compared Hemoccult and OC-
Hemodia in a randomised trial. Immunochemical faecal occult
blood test showed a higher DR for cancer and advanced adenomas
than guaiac test.
Comparing the performance of our reference strategy with the
results of Dutch study, it can be noted that PR was substantially
similar in the two settings, whereas our detection rates for cancer
and advanced adenoma were lower than those found in the Dutch
study (24 vs 18.4%). Likewise, the PPV for significant neoplasia
was higher in the van Rossum study compared to those registered
Table 5 Positivity rate (PR), number of screen detected cancers and advanced adenomas, number of colonoscopies, detection rate (DR) of cancers and
advanced adenomas (per 1000 screened subjects) and number needed to scope (NTS)
a to find a cancer or a significant neoplasia
b by screening strategy
Strategy PR% Number (difference %) DR (%) NTS
a
Positive
samples
Cutoff
(ngml
 1) Cancer
Advanced
adenomas Colonoscopies Cancer
Advanced
adenomas Cancer
Significant
neoplasia
b
At least one X80 8.0 69 (+21.1) 465 (+44.4) 1465 (+77.2) 3.4 22.6 21.2 2.7
At least one X100 6.7 69 (+21.1) 406 (+26.1) 1221 (+47.6) 3.4 19.7 17.7 2.6
At least one X120 5.9 67 (+17.5) 380 (+18.0) 1082 (+30.8) 3.3 18.5 16.2 2.4
One X80 5.5 59 (+3.5) 368 (+14.3) 1001 (+21.0) 2.9 17.9 17.0 2.3
One
c (reference) X100
c 4.5 57 322 827 2.8 15.6 14.5 2.2
One X120 4.0 56 ( 1.8) 301 ( 6.5) 737 ( 10.9) 2.7 14.6 13.2 2.1
Both X80 2.8 47 ( 17.5) 254 ( 21.1) 515 ( 37.7) 2.3 12.3 11.0 1.7
Both X100 2.3 44 ( 22.8) 220 ( 31.7) 423 ( 48.9) 2.1 10.7 9.6 1.6
Both X120 2.0 44 ( 22.8) 206 ( 36.0) 380 ( 54.1) 2.1 10.0 8.6 1.5
Differences (%) of number of cancers, advanced adenomas and colonoscopies with reference strategy are given in brackets.
aNTS: number of FOBT+ colonoscopies needed to
find a cancer or a significant neoplasia.
bSignificant neoplasia: cancer+advanced adenomas (any adenoma larger than 9mm, and/or with a villous histological component higher
than 20%, and/or with severe dysplasia).
cReference strategy: 1-day and cutoff X100ngml
 1.
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two studies should be taken with caution, as difference in detection
rates could also relate to other confounding variables, such as a
higher prevalence of lesions in Dutch population (Ferlay et al,
2007) compared to Italian population.
The reference strategy results in our study are consistent with
those reported by the survey of Italian screening programmes
(Zorzi et al, 2008) as far as diagnostic indicators (PR, DR and PPV)
and compliance to assessment are concerned. This means that the
population enrolled in this study is representative of the general
population complying with the screening invitation, thus suggest-
ing a safe generalisability of results.
One of the most important factors to be taken into account when
choosing a screening strategy is the acceptability of the test.
Several studies (Federici et al, 2005; van Rossum et al, 2008)
showed a higher participation rate of invited subjects to 1-day
IFOBT compared to 3-day guaiac screening. Several reasons may
account for such a preference, such as the absence of dietary
restrictions, a better hygiene in handling faecal samples and no
need for multiple sampling.
In this study, no remarkable differences in participation rate
were observed in every screening programmes involved in the
study compared to that observed in resident subjects in the same
areas, invited to the routine 1-day test screening.
Another important aspect of screening test acceptability is the
easiness of sampling execution. Theoretically, multiple samplings
should be more difficult to obtain and more unpleasant to handle,
as subjects must store the first samples waiting the final one. In
this study, only 22 of 20596 recruited subjects did not return a
second sample; this, together with the low rate of not acceptance to
enter the study and the observation that attendance was similar to
that registered by local service screening, using one-day sampling,
suggests that the 2-day testing probably is not a major barrier to
compliance with test returning.
It is well known that it takes many years for an advanced
adenoma to progress (if at all) to CRC, and such a time window
allows for cumulative sensitivity to be achieved by repeat
screening. Therefore, a programme with a high compliance at
repeat screening might favour a screening test with a lower one-
shot sensitivity. On the contrary, when low compliance is expected
at repeat screening, choosing a strategy with a high DR per single
screening episode might be crucial.
A second relevant factor to be taken into account is the
colonoscopy workload associated with a given strategy. Minimising
PR is recommendable, as colonoscopy is an unpleasant and
potentially harmful procedure, and accounts for a relevant part
(about 50%) of total screening costs (Castiglione et al, 1997). The
effect of different strategies on colonoscopy workload is quite
variable; compared to the reference strategy, the number of
required colonoscopies may vary from  54 (more specific) to
þ77% (more sensitive), whereas that of detected cancer may vary
from  23 to þ21%. Identifying the optimal strategy was not the
aim of this study; however, although based on a limited sample
size, our data suggest that minimising PR (by adopting the most
specific strategy) is associated to a substantial loss in the DR,
whereas, on the other hand, maximising the DR (by adopting the
most sensitive strategy) is associated to hardly acceptable recall
rate. Our study shows that different strategies modulate a
continuum of opposite changes in sensitivity and specificity.
Deciding the optimal cutoff, particularly in the absence of evidence
of the efficacy of different strategies, is very difficult and may
depend more on considerations of local resources (e.g., colono-
scopy facilities) than purely on expected accuracy.
Colonoscopies needed to detect one cancer (i.e., the inverse of
PPV) range from 21.2 with the less specific to 8.6 with the most
specific strategy, whereas corresponding figures to detect one
significant neoplasia (cancerþadvanced adenoma) are between
2.7 and 1.5, respectively (see Table 5). In this study, recruited
subjects were in their first screening examination. The PPV is
expected to decrease in repeat screening, due to a lower prevalence
of disease; such a decrease may not have an impact on the
differences between different strategies, but a recent study by
Van Rossum et al (2008) suggests to increase the positivity threshold
when resources are limited and CRC prevalence is presumably low.
As far as sensitivity is concerned, it is worth noting that different
strategies seem to have a greater impact on advanced adenomas
rather than on cancer DR. In fact, the more sensitive strategy
(2-day sampling, at least one sample X80ngml
 1) would obtain a
54% higher cancer DR (3.4 vs 2.1%) compared to a less sensitive
strategy (2-day sampling with both positive results at
X120ngml
 1), whereas the DR for advanced adenomas would
be more than double (þ120%, 22.6 vs 10.0%). The study of
Guittet et al (2007) also supports the hypothesis that lowering
IFOBT threshold will increase the DR of advanced adenomas more
than the DR of cancer.
CONCLUSIONS
In conclusion, none of the screening strategies analysed in our
study showed a clear-cut superiority of results, but we observed a
continuum of results for all performance indicators while passing
from more specific to more sensitive strategies. The findings of
this study do not provide an ultimate answer to which is the best
CRC screening strategy, but they may provide an helpful guidance
when deciding on the implementation screening protocols, and
when considering how to adapt a screening strategy to the
underlying context, based on CRC epidemiology, observed (or
expected) programme performance with respect to compliance to
invitation, DR and PPV and the available resources.
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